Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures
Clinical trial NCT01648101 · TERMINATED
Trial details
- NCT number
- NCT01648101
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-29
- Primary completion
- 2013-12-01
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.